{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:05:46Z","timestamp":1793379946108,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0077\/2024\/AGJ"],"award-info":[{"award-number":["0077\/2024\/AGJ"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0014\/2023\/AKP"],"award-info":[{"award-number":["0014\/2023\/AKP"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0002\/2025\/NRP"],"award-info":[{"award-number":["0002\/2025\/NRP"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12072-026-11071-x","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:47:40Z","timestamp":1773074860000},"page":"575-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["mRNA vaccines for hepatocellular carcinoma: mechanisms, therapeutic strategies, and clinical perspectives"],"prefix":"10.1007","volume":"20","author":[{"given":"Zixin","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-2984","authenticated-orcid":false,"given":"Chengwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"3","key":"11071_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"11071_CR2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","volume":"79","author":"AD Ladd","year":"2024","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2024;79(4):926\u2013940","journal-title":"Hepatology"},{"issue":"11","key":"11071_CR3","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.3390\/curroncol30110711","volume":"30","author":"F Bicer","year":"2023","unstructured":"Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Advances in immunotherapy for hepatocellular carcinoma (HCC). Curr Oncol. 2023;30(11):9789\u20139812","journal-title":"Curr Oncol"},{"issue":"3","key":"11071_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u2013172","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"11071_CR5","volume":"1879","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yan Q, Zeng Z, Fan C, Xiong W. Advances and prospects of mRNA vaccines in cancer immunotherapy. Biochimica et Biophysica Acta (BBA). 2024;1879(2): 189068","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"19","key":"11071_CR6","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1016\/j.molcel.2024.08.036","volume":"84","author":"TJ Carrocci","year":"2024","unstructured":"Carrocci TJ, Neugebauer KM. Emerging and re-emerging themes in co-transcriptional pre-mRNA splicing. Mol Cell. 2024;84(19):3656\u20133666","journal-title":"Mol Cell"},{"key":"11071_CR7","unstructured":"Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002. Chapter 6, How Cells Read the Genome: From DNA to Protein. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK21054\/. Accessed Oct 2025."},{"issue":"10","key":"11071_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u2013780","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"11071_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41594-023-01196-0","volume":"31","author":"J Brito Querido","year":"2024","unstructured":"Brito Querido J, Sokabe M, D\u00edaz-L\u00f3pez I, Gordiyenko Y, Fraser CS, Ramakrishnan V. The structure of a human translation initiation complex reveals two independent roles for the helicase eIF4A. Nat Struct Mol Biol. 2024;31(3):455\u2013464","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"11071_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2017","unstructured":"Leppek K, Das R, Barna M. Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2017;19(3):158\u2013174","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"16","key":"11071_CR11","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1073\/pnas.1404819111","volume":"111","author":"CT Caskey","year":"2014","unstructured":"Caskey CT, Leder P. The RNA code: nature\u2019s Rosetta Stone. Proc Natl Acad Sci U S A. 2014;111(16):5758\u20135759","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11071_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034728","author":"C Mayr","year":"2019","unstructured":"Mayr C. What are 3\u2019 UTRs doing? Cold Spring Harb Perspect Biol. 2019. https:\/\/doi.org\/10.1101\/cshperspect.a034728","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"11071_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","volume":"23","author":"LA Passmore","year":"2022","unstructured":"Passmore LA, Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2022;23(2):93\u2013106","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"11071_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u20131094","journal-title":"Nat Rev Mater"},{"issue":"11","key":"11071_CR15","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u20131840","journal-title":"Mol Ther"},{"key":"11071_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17249-1","author":"T Chen","year":"2022","unstructured":"Chen T, Potapov V, Dai N, Ong JL, Roy B. N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/s41598-022-17249-1","journal-title":"Sci Rep"},{"issue":"2","key":"11071_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165\u2013175","journal-title":"Immunity"},{"issue":"25","key":"11071_CR18","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RWJ, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u20132450","journal-title":"N Engl J Med"},{"issue":"1","key":"11071_CR19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41467-025-57149-2","volume":"16","author":"Y Xue","year":"2025","unstructured":"Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, et al. LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment. Nat Commun. 2025;16(1):2198","journal-title":"Nat Commun"},{"issue":"7","key":"11071_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","volume":"72","author":"S Van Lint","year":"2012","unstructured":"Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661\u20131671","journal-title":"Cancer Res"},{"key":"11071_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003978","author":"D Reparaz","year":"2022","unstructured":"Reparaz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, et al. Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003978","journal-title":"J Immunother Cancer"},{"issue":"12","key":"11071_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41422-025-01199-0","volume":"35","author":"H Zhao","year":"2025","unstructured":"Zhao H, Cheng Y, Zhang T, Wang Q, Xu Y, Wang G, et al. Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma. Cell Res. 2025;35(12):970\u2013986","journal-title":"Cell Res"},{"issue":"28","key":"11071_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn3628","volume":"10","author":"ME Camarena","year":"2024","unstructured":"Camarena ME, Theunissen P, Ruiz M, Ruiz-Orera J, Calvo-Serra B, Castelo R, et al. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort. Sci Adv. 2024;10(28): eadn3628","journal-title":"Sci Adv"},{"issue":"11","key":"11071_CR24","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976\u20135988","journal-title":"J Clin Invest"},{"issue":"23","key":"11071_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33(23): e2007603","journal-title":"Adv Mater"},{"key":"11071_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975408","volume":"12","author":"Z Deng","year":"2022","unstructured":"Deng Z, Yang H, Tian Y, Liu Z, Sun F, Yang P. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol. 2022;12: 975408","journal-title":"Front Oncol"},{"issue":"1","key":"11071_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0431-x","volume":"6","author":"I Lai","year":"2018","unstructured":"Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, et al. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer. 2018;6(1): 125","journal-title":"J Immunother Cancer"},{"issue":"1","key":"11071_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28279-8","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022;13(1): 758","journal-title":"Nat Commun"},{"issue":"1","key":"11071_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02480-x","volume":"24","author":"C Meng","year":"2025","unstructured":"Meng C, Zhang H, Yi X, Kong G, Zhang X, Wang B, et al. Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system. Mol Cancer. 2025;24(1): 258","journal-title":"Mol Cancer"},{"issue":"1","key":"11071_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03681-8","volume":"23","author":"Y Wu","year":"2025","unstructured":"Wu Y, Sun G, Ren W, Gui Y, Wang C, Ye X, et al. Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model. J Nanobiotechnology. 2025;23(1): 602","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"11071_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00449-w","volume":"11","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Gao F, Chang Y, Zhao Q, He X. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. Biomark Res. 2023;11(1): 6","journal-title":"Biomark Res"},{"key":"11071_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001605","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Li Y, Wu T, Cao L, Xu G, Liu J, et al. GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001605","journal-title":"Hepatology"},{"issue":"4","key":"11071_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30(4):1044\u20131053","journal-title":"Nat Med"},{"issue":"1","key":"11071_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0636-8","volume":"11","author":"MW L\u00f6ffler","year":"2019","unstructured":"L\u00f6ffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schr\u00f6eder CM, et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 2019;11(1): 28","journal-title":"Genome Med"},{"issue":"41","key":"11071_CR35","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/s41388-024-03140-y","volume":"43","author":"H Han","year":"2024","unstructured":"Han H, Shi Q, Zhang Y, Ding M, He X, Liu C, et al. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation. Oncogene. 2024;43(41):3062\u20133077","journal-title":"Oncogene"},{"issue":"10427","key":"11071_CR36","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u2013644","journal-title":"Lancet"},{"issue":"1","key":"11071_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010059","volume":"16","author":"R Han","year":"2023","unstructured":"Han R, Wang Y, Lu L. Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment. Pharmaceutics. 2023;16(1): 59","journal-title":"Pharmaceutics"},{"key":"11071_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054231","volume":"12","author":"Y Cai","year":"2022","unstructured":"Cai Y, Chen R, Gao S, Li W, Liu Y, Su G, et al. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front Oncol. 2022;12: 1054231","journal-title":"Front Oncol"},{"key":"11071_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep35056","volume":"6","author":"J Tu","year":"2016","unstructured":"Tu J, Ding Y, Ying X, Wu F, Zhou X, Zhang D, et al. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 2016;6: 35056","journal-title":"Sci Rep"},{"key":"11071_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455019","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Hu L, Wang Y, Liu Q, Liu J, Long H, et al. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. Front Immunol. 2024;15: 1455019","journal-title":"Front Immunol"},{"issue":"1","key":"11071_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-021-02969-6","volume":"71","author":"T Yamauchi","year":"2022","unstructured":"Yamauchi T, Hoki T, Oba T, Kajihara R, Attwood K, Cao X, et al. CD40 and CD80\/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells. Cancer Immunol Immunother. 2022;71(1):137\u2013151","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"11071_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54877-9","volume":"15","author":"AEI Hamouda","year":"2024","unstructured":"Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat Commun. 2024;15(1): 10635","journal-title":"Nat Commun"},{"issue":"40","key":"11071_CR43","doi-asserted-by":"publisher","first-page":"43005","DOI":"10.18632\/oncotarget.5656","volume":"6","author":"KC Soares","year":"2015","unstructured":"Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, et al. TGF-\u03b2 blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015;6(40):43005\u201343015","journal-title":"Oncotarget"},{"issue":"1","key":"11071_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Shi M, Wang Y, You J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct Target Ther. 2024;9(1): 322","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"11071_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u2013229","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"11071_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004389","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, et al. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J Immunother Cancer. 2022;10(9): e004389","journal-title":"J Immunother Cancer"},{"key":"11071_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100159","volume":"13","author":"D Tsilingiris","year":"2022","unstructured":"Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metab Open. 2022;13: 100159","journal-title":"Metab Open"},{"issue":"7","key":"11071_CR48","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4251\/wjgo.v13.i7.673","volume":"13","author":"P Chen","year":"2021","unstructured":"Chen P, Fang Q, Chen D, Chen H. Neoantigen vaccine: an emerging immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13(7):673\u2013683","journal-title":"World J Gastrointest Oncol"},{"key":"11071_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","volume":"159","author":"D Witzigmann","year":"2020","unstructured":"Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev. 2020;159:344\u2013363","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"11071_CR50","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/nmat4718","volume":"15","author":"KM Tsoi","year":"2016","unstructured":"Tsoi KM, MacParland SA, Ma XZ, Spetzler VN, Echeverri J, Ouyang B, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater. 2016;15(11):1212\u20131221","journal-title":"Nat Mater"},{"key":"11071_CR51","unstructured":"U.S. Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Rockville, MD: U.S. Department of health and human services, FDA, center for drug evaluation and research (CDER), center for biologics evaluation and research (CBER); 2003. https:\/\/www.fda.gov\/media\/71311\/download. Accessed Oct 2025."},{"key":"11071_CR52","unstructured":"U.S. Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Rockville, MD: U.S. Department of health and human services, FDA, center for drug evaluation and research (CDER); 2009. https:\/\/www.fda.gov\/media\/116737\/download. Accessed Oct 2025."},{"issue":"4","key":"11071_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1053\/j.gastro.2024.05.017","volume":"167","author":"MB Hilscher","year":"2024","unstructured":"Hilscher MB, Wysokinski WE, Andrews JC, Simonetto DA, Law RJ, Kamath PS. Portal vein thrombosis in the setting of cirrhosis: evaluation and management strategies. Gastroenterology. 2024;167(4):664\u2013672","journal-title":"Gastroenterology"},{"key":"11071_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154-155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"11071_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","volume":"73","author":"J Trebicka","year":"2020","unstructured":"Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73(4):842\u2013854","journal-title":"J Hepatol"},{"issue":"3","key":"11071_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/mt.2011.294","volume":"20","author":"RL Kanasty","year":"2012","unstructured":"Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513\u2013524","journal-title":"Mol Ther"},{"issue":"3","key":"11071_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrgastro.2015.219","volume":"13","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol. 2016;13(3):131\u2013149","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11071-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:01:57Z","timestamp":1783148517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11071-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["11071"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11071-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for publication statement"}}]}}